Purine L-nucleosides, analogs and uses thereof

• US 6,509,320 B1
• Filed: 06/15/2000
• Issued: 01/21/2003
• Est. Priority Date: 10/16/1996
• Status: Expired due to Fees

• Current Assignee: Anadys Pharmaceuticals Inc. (Roche Holding AG)
• Original Assignee: ICN Pharmaceuticals, Inc (Bausch Health Cos., Inc.)
• Inventors: Averett, Devron, Wang, Guangyi, Tam, Robert
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): CRANE, LAWRENCE E
• Application Number:
  US09/594,271
• Time in Patent Office: 950 Days
• Field of Search: 514/43, 514/45, 536/27.21, 536/27.81
• US Class Current: 514/43
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7056 containing five-membered rings with nitrogen as a ring hetero atom
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61K 31/7115 Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C07H 19/04 Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
• CPC Class Codes: C07H 19/16 Purine radicals

Abstract

Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.

Claims

1. A compound having a structure according to Formula 1:

3. A pharmaceutical comprising a compound according to claims 1 or 2, or a pharmaceutically acceptable ester or salt thereof, admixed with at least one pharmaceutically acceptable carrier.

2. A compound having a structure according to Formula 4: